美国成人ECMO支持与心脏移植后结局
该研究基于UNOS登记数据,分析2000年后157例ECMO支持的成人心脏移植受者,发现移植后1年生存率57.8%,44.6%死亡且61.4%发生在术后30天内;合并肾功能不全与机械通气的患者生存显著更差。
要点
- ECMO支持成人心脏移植后早期死亡率高,1年生存率57.8%。
- 术后30天存活者长期生存可接受,1年82.3%、5年76.2%。
- 合并肾功能不全与机械通气者移植后生存显著更差。
核心结论
- 当代ECMO支持成人心脏移植后死亡率未改善,肾功能不全合并机械通气者生存显著更差。
研究设计与样本
- 回顾性队列分析UNOS登记中2000年1月1日后157例ECMO支持的成人心脏移植受者。
主要发现
- 随访中位0.55年,44.6%死亡,其中61.4%死于术后30天内。
- 术后30天存活者1年生存82.3%、5年生存76.2%。
- 术后卒中发生率10.1%,需透析者28.1%。
- 2009年前后移植生存无差异(单因素HR 0.84,95%CI 0.51-1.38,p=0.48)。
- 合并肾功能不全与机械通气者30天和1年生存分别为29.4%和12.5%,无二者为78.7%和71.4%。
关键数值与推荐
- 肾功能不全定义为eGFR<45 ml/min/1.73 m2或透析。
- 合并机械通气与肾功能不全交互作用p<0.05。
临床怎么用
- 对ECMO支持心脏移植候选人应评估肾功能不全与机械通气状态以预测移植后生存。
- 需重新审视ECMO支持患者的优先分配政策以优化供心分配。
局限性
- 回顾性登记研究,样本量157例,随访中位仅0.55年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients supported with extracorporeal membrane oxygenation (ECMO) are given priority listing status for heart transplant (HT). Data on post-HT outcomes for adults with ECMO support at the time of HT are limited. METHODS: We analyzed data from the United Network for Organ Registry (UNOS) registry for 157 ECMO-supported adults (age ≥ 18 years) undergoing HT after January 1, 2000. Data at the time of HT were examined for their association with post-transplant mortality using multivariable Cox proportional hazard analyses. RESULTS: Patients (69.4% males; mean age, 46.0 ± 15.6 years; 15.9% African Americans) were monitored for median of 0.55 years (interquartile range, 0.04-4.5). Seventy patients (44.6%) died during follow-up (survival at 1 year was 57.8%), of which 43 (61.4%) died within 30 days post-HT. For patients surviving the first 30 days after transplant, long-term survival was acceptable (82.3% at 1 year and 76.2% at 5 years). Prevalence of immediate post-HT complications, such as stroke and need for dialysis, were 10.1% and 28.1%, respectively. Post-HT survival did not differ between those who received an allograft before and after January 1, 2009 (univariate hazard ratio, 0.84; 95% confidence interval, 0.51-1.38; p = 0.48). Among the predictors identified for 30-day and long-term mortality were recipient history of renal insufficiency (RI; defined as estimated glomerular filtration rate < 45 ml/min/1.73 m2 or dialysis) and mechanical ventilation (MV; interaction p < 0.05); those with both MV and RI had significantly poorer post-transplant survival (29.4% and 12.5% for 30-day and 1-year survival, respectively) compared with those without (78.7% and 71.4% for 30-day and 1-year survival, respectively). CONCLUSIONS: Post-HT mortality did not change for ECMO-supported adults in the contemporary era, and those with RI and MV had significantly poorer post-transplant survival. A critical review of priority listing status for ECMO-supported patients is warranted for optimal allocation and outcomes of cardiac allografts.
引用
- Zalawadiya S, Fudim M, Bhat G, et al. Extracorporeal membrane oxygenation support and post-heart transplant outcomes among United States adults. J Heart Lung Transplant. 2016. PMID: 27866925. doi:10.1016/j.healun.2016.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。